Megan Garlapow, PhD

All articles by Megan Garlapow, PhD

• Study shows most children with mastocytosis improve over time

  Most children with mastocytosis limited to the skin improve or fully resolve, often within a few years, rather than progress to SM.

• FDA accepts New Drug Application for bezuclastinib in nonadvanced SM

  The application is supported by results from the SUMMIT trial. A decision is expected by December 30, 2026.

• Case report reveals hidden systemic mastocytosis behind bone lesions

  Aggressive SM should be considered in older adults with unexplained symptoms when no primary cancer is identified.

• Review explores impact of targeted KIT drugs on SM anaphylaxis

  KIT-targeting drugs can lower abnormal mast cell burden and reduce the frequency and severity of life-threatening reactions.

• Study reveals gap in how indolent systemic mastocytosis control is viewed

  Only 25% of patients with indolent SM report their disease is well controlled, despite most clinicians believing control is common.

• FDA requests packaging fixes for dibutepinephrine film

  If approved, dibutepinephrine could offer patients with SM a needle-free epinephrine option that is easier to carry and use.

• Testing GI tissue improves detection of systemic mastocytosis

  Gastrointestinal mastocytosis occurs in about one-third of patients with systemic mastocytosis and strongly predicts bone marrow involvement.

• Telomere shortening may explain why childhood mastocytosis often fades

  Research on shortened telomeres in children’s mast cells may help develop ways to trigger natural disease remission in SM.

• FDA grants Breakthrough Designation to bezuclastinib for nonadvanced SM

  Bezuclastinib received Breakthrough Therapy Designation from the FDA for certain patients with nonadvanced SM.

• Genetic findings reveal new clues for systemic mastocytosis

  Scientists found five genetic changes in people with systemic mastocytosis (SM), including two never reported before.